The International Collaboration on Cosmetics Safety ushers in a new phase as its 2026 Board officers take their roles, strengthening its worldwide dedication to promoting animal-free innovations in cosmetics safety science amid swift regulatory and scientific shifts.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collaboration, bringing together diverse stakeholders who share a common objective: accelerating the global adoption and acceptance of animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers underscores the organization’s intention to maintain strategic focus while navigating an increasingly complex international landscape, where expectations for ethical research, scientific rigor, and regulatory alignment continue to evolve.
Continued leadership stability and expansive global representation
The 2026 Board leadership unites senior leaders from the cosmetics, consumer goods, and regulatory advocacy fields, capturing the multi-stakeholder character that has shaped ICCS from the start. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been chosen again to serve as Chair of the Board of Directors. His renewed appointment reflects sustained trust in a leadership style grounded in scientific rigor, international collaboration, and productive dialogue with regulatory authorities.
Serving with him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose extensive record in industry advocacy and regulatory collaboration delivers a solid regional perspective shaped by policy expertise. The position of Secretary will be taken on by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, contributing wide-ranging knowledge in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been named Treasurer, providing deep leadership experience in toxicology and organizational governance.
Together, the officers form a Board leadership team that spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than advocacy for any single sector. This balance is central to the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Advancing animal-free scientific innovation through united collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment methods, when rigorously designed and validated, are not only ethically favorable but also scientifically stronger. Since its establishment in early 2023, ICCS has sought to show that non-animal approaches can deliver dependable, relevant insights to safeguard both human well-being and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing involvement from regulators worldwide.
Throughout 2025, ICCS introduced a range of initiatives that reinforced its scientific base and broadened its reach. Among these efforts was the publication of a Best Practice Guidance document, created to offer clearer direction and greater uniformity in applying animal-free safety assessment methods. The guidance sought to connect scientific advances with regulatory needs, delivering a practical framework that stakeholders could use when generating or reviewing non‑animal evidence.
In parallel, ICCS contributed to shaping new methodologies consistent with next generation risk assessment (NGRA), an evolving framework that draws on advanced in vitro, in silico, and exposure-driven strategies. These methods are now widely regarded as fundamental to contemporary toxicology, offering more human-relevant insights while limiting dependence on animal studies. ICCS’ engagement in this field underscores its dedication to promoting both ethical progress and scientific rigor.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A pivotal milestone reshaping the oversight of cosmetics safety
The selection of the 2026 Board officers unfolds amid a period of major shifts in global cosmetics regulation, as numerous markets revisit long‑standing testing mandates in response to evolving public expectations, scientific progress, and broader international policy developments. Within this landscape, organizations such as ICCS hold an essential role by helping bridge innovation and regulatory demands, ensuring that advancement remains both trustworthy and sustainable.
ICCS leadership has long underscored that moving toward animal‑free safety science cannot progress through isolated initiatives; rather, it demands synchronized engagement from industry, academia, regulatory bodies, and civil society. The Board’s makeup embodies this principle by uniting figures who grasp the technical, regulatory, and organizational aspects required to drive meaningful transformation.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair highlighted how crucial it is to harness ICCS’ global, multi-stakeholder framework to narrow the divide between innovation and regulation, ensuring that progress in animal-free science moves beyond laboratories and becomes reliable, consistently applicable tools that regulators can confidently use.
Strengthening foundations for long-term impact
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education remains a core element of ICCS’ strategy, as the organization works to provide accessible, science‑based resources and forums for discussion that illuminate the foundations of animal‑free safety science and enable well‑informed decision‑making. This mission becomes particularly crucial in a field where misconceptions or uneven expertise may slow progress, even when the underlying science is strong.
The organization’s structure, encompassing leading cosmetics and ingredient producers alongside trade and research groups as well as animal protection organizations, places it in a distinctive position to tackle these challenges. This broad range of viewpoints helps keep discussions balanced, well‑rooted, and oriented toward common objectives rather than limited agendas.
Based in New York, ICCS remains active as a global initiative that underscores the inherently international landscape of cosmetics research and regulation. As products and ingredients frequently cross national borders, aligning standards and encouraging mutual acceptance of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science around the world.
In confirming its 2026 Board officers, ICCS signals both stability and forward momentum. The leadership team brings continuity from a year marked by concrete achievements, alongside the experience and perspective needed to navigate the next phase of change. As scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a convener and catalyst for animal-free cosmetics safety science is set to become even more relevant.
Ultimately, the significance of the 2026 Board elections lies not only in the individuals appointed, but in what their leadership represents: a sustained commitment to collaboration, scientific integrity, and the responsible advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to translate vision into lasting impact, shaping the future of cosmetics safety in a way that aligns ethics, science, and global public trust.
